EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 33 / No 10 (Octobre 2017) Med Sci (Paris), 33 10 (2017) 871-877 References
Free Access
Issue
Med Sci (Paris)
Volume 33, Number 10, Octobre 2017
Page(s) 871 - 877
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173310019
Published online 10 October 2017
  1. Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I. Molecular mechanisms of activation and regulation. Front Immunol 2015; 6 : 262. [PubMed] [Google Scholar]
  2. Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system part II: role in immunity. Front Immunol 2015 ; 6 : 257. [PubMed] [Google Scholar]
  3. Gaboriaud C, Ling WL, Thielens NM, et al. Deciphering the fine details of c1 assembly and activation mechanisms: “mission impossible”?. Front Immunol 2014 ; 5 : 565. [CrossRef] [PubMed] [Google Scholar]
  4. Bonavita E, Gentile S, Rubino M, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015 ; 160 : 700–714. [CrossRef] [PubMed] [Google Scholar]
  5. Nauta AJ, Trouw LA, Daha MR, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002 ; 32 : 1726–1736. [CrossRef] [PubMed] [Google Scholar]
  6. Dobó J, Pál G, Cervenak L, et al. The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond. Immunol Rev 2016 ; 274 : 98–111. [CrossRef] [PubMed] [Google Scholar]
  7. Ricklin D, Reis ES, Mastellos DC, et al. Complement component C3 - The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev 2016 ; 274 : 33–58. [CrossRef] [PubMed] [Google Scholar]
  8. Morgan BP, Walters D, Serna M, et al. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunol Rev 2016 ; 274 : 141–151. [CrossRef] [PubMed] [Google Scholar]
  9. Chauvet S, Marinozzi MC, Le Quintrec M, et al. Spectre des anomalies du complément associées aux glomérulopathies à dépôts de C3: quoi de neuf en 2014 ?. Néphrologie Thérapeutique 2014 ; 10 : 280–281. [CrossRef] [Google Scholar]
  10. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol 2016 ; 12 : 383–401. [CrossRef] [PubMed] [Google Scholar]
  11. Ajona D, Pajares MJ, Corrales L, et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst 2013 ; 105 : 1385–1393. [CrossRef] [PubMed] [Google Scholar]
  12. Imamura T, Yamamoto-Ibusuki M, Sueta A, et al. Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer Tokyo Jpn 2016 ; 23 : 876–885. [CrossRef] [Google Scholar]
  13. Chen J, Wu W, Chen L, et al. Expression and clinical significance of AHSG and complement C3 in pancreatic ductal adenocarcinoma. Zhonghua Yi Xue Za Zhi 2014 ; 94 : 2175–2179. [PubMed] [Google Scholar]
  14. Xi W, Liu L, Wang J, et al. High level of anaphylatoxin C5a predicts poor clinical outcome in patients with clear cell renal cell carcinoma. Sci Rep 2016 ; 6 : 29177. [CrossRef] [PubMed] [Google Scholar]
  15. Chang IW, Lin VCH, Wu WJ, et al. Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. J Cancer 2016 ; 7 : 1396–1405. [CrossRef] [PubMed] [Google Scholar]
  16. Riihilä PM, Nissinen LM, Ala-aho R, et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 2014 ; 134 : 498–506. [CrossRef] [PubMed] [Google Scholar]
  17. Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003 ; 40 : 109–123. [Google Scholar]
  18. Cho MS, Vasquez HG, Rupaimoole R, et al. Autocrine effects of tumor-derived complement. Cell Rep 2014 ; 6 : 1085–1095. [CrossRef] [PubMed] [Google Scholar]
  19. Hong Q, Sze CI, Lin SR, et al. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One 2009 ; 4 : e5755. [CrossRef] [PubMed] [Google Scholar]
  20. Maeda Y, Kawano Y, Wada Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep 2015 ; 33 : 1844–1850. [CrossRef] [PubMed] [Google Scholar]
  21. Lu Y, Hu XB. C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncol Rep 2014 ; 32 : 2817–2823. [CrossRef] [PubMed] [Google Scholar]
  22. Cho MS, Rupaimoole R, Choi HJ, et al. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. J Immunol 2016 ; 196 : 1412–1418. [CrossRef] [PubMed] [Google Scholar]
  23. Piao C, Cai L, Qiu S, et al. Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. J Biol Chem 2015 ; 290 : 10667–10676. [CrossRef] [PubMed] [Google Scholar]
  24. Kaida T, Nitta H, Kitano Y, et al. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget 2016 ; 7 : 84798–84809. [CrossRef] [PubMed] [Google Scholar]
  25. Nitta H, Murakami Y, Wada Y, et al. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep 2014 ; 32 : 1715–1719. [CrossRef] [PubMed] [Google Scholar]
  26. Bulla R, Tripodo C, Rami D, et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun 2016 ; 7 : 10346. [CrossRef] [PubMed] [Google Scholar]
  27. Rozanov DV, Sikora S, Godzik A, et al. Non-proteolytic, receptor/ligand interactions associate cellular membrane type-1 matrix metalloproteinase with the complement component C1q. J Biol Chem 2004 ; 279 : 50321–50328. [CrossRef] [PubMed] [Google Scholar]
  28. Vlaicu SI, Tegla CA, Cudrici CD, et al. Role of C5b–9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res 2013 ; 56 : 109–121. [CrossRef] [PubMed] [Google Scholar]
  29. Kaur A, Sultan SHA, Murugaiah V, et al. Human C1q induces apoptosis in an ovarian cancer cell line via tumor necrosis factor pathway. Front Immunol 2016; 7. [Google Scholar]
  30. Nabizadeh JA, Manthey HD, Steyn FJ, et al. The Complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. J Immunol 2016 ; 196 : 4783–4792. [CrossRef] [PubMed] [Google Scholar]
  31. Janelle V, Langlois M-P, Tarrab E, et al. Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol Res. 2014 ; 2 : 200–206. [CrossRef] [PubMed] [Google Scholar]
  32. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008 ; 9 : 1225–1235. [CrossRef] [PubMed] [Google Scholar]
  33. Corrales L, Ajona D, Rafail S, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012 ; 189 : 4674–4683. [CrossRef] [PubMed] [Google Scholar]
  34. Gunn L, Ding C, Liu M, et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012 ; 189 : 2985–2994. [CrossRef] [PubMed] [Google Scholar]
  35. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003 ; 9 : 653–660. [CrossRef] [PubMed] [Google Scholar]
  36. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011 ; 58 : 7162–7164. [Google Scholar]
  37. Bossi F, Tripodo C, Rizzi L, et al. C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci USA 2014 ; 111 : 420914. [CrossRef] [Google Scholar]
  38. Nunez-Cruz S, Gimotty PA, Guerra MW, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012; 14 : 994-IN1. [Google Scholar]
  39. Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res 2014 ; 59 : 203–210. [CrossRef] [PubMed] [Google Scholar]
  40. Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. mAbs 2014; 6 : 1133–1144. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.